tiprankstipranks
Trending News
More News >
Angiodynamics, Inc. (ANGO)
:ANGO
US Market
Advertisement

AngioDynamics (ANGO) Earnings Dates, Call Summary & Reports

Compare
462 Followers

Earnings Data

Report Date
Oct 02, 2025
Before Open (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
-0.12
Last Year’s EPS
-0.11
Same Quarter Last Year
Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Jul 15, 2025|
% Change Since: 6.47%|
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth, particularly in the MedTech segment, successful product performance, and operational efficiency improvements. However, the impact of tariffs and a decline in NanoKnife capital sales were noted challenges.
Company Guidance -
Q1 2026
During the AngioDynamics Fiscal Year 2025 Fourth Quarter Earnings Call, the company provided detailed guidance for fiscal year 2026, anticipating net sales between $305 million and $310 million, reflecting a growth rate of 4% to 6% over the previous year. The MedTech segment is projected to grow by 12% to 15%, while the med device segment is expected to remain flat. The company also issued a gross margin forecast of 53.5% to 55.5%, factoring in a potential $4 to $6 million tariff impact. Absent this impact, gross margins would be in the range of 55% to 56%. Adjusted EBITDA is expected to range from $3 million to $8 million, and adjusted loss per share is projected between negative $0.35 and negative $0.25, again considering potential tariff impacts. AngioDynamics remains optimistic about being cash flow positive for the full fiscal year, emphasizing its strategic transformation and operational efficiency initiatives to support sustainable growth.
Strong Revenue Growth
Total revenue for the fourth quarter was $80.2 million, representing a growth of over 12% year-over-year. MedTech growth was over 20% and med device growth was more than 6%.
Auryon Platform Success
Auryon has delivered its sixteenth consecutive quarter of double-digit increases, with revenue reaching $15.6 million, growing 19.7% compared to last year.
Mechanical Thrombectomy Growth
The mechanical thrombectomy portfolio showed approximately 45% year-over-year growth, with AngioVac and AlphaVac contributing significantly.
Operational Efficiency
Generated positive adjusted EBITDA and over $15 million of free cash flow in the fourth quarter. Expecting $15 million in annualized savings by fiscal 2027.
NanoKnife and Regulatory Milestones
NanoKnife achieved key clinical, reimbursement, and regulatory milestones with a CPT Category I code granted for prostate and liver treatments effective January 1, 2026.

AngioDynamics (ANGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ANGO Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 02, 2025
2026 (Q1)
-0.12 / -
-0.11
Jul 15, 2025
2025 (Q4)
-0.12 / -0.03
-0.0650.00% (+0.03)
Apr 02, 2025
2025 (Q3)
-0.13 / -0.08
-0.1650.00% (+0.08)
Jan 08, 2025
2025 (Q2)
-0.11 / -0.04
-0.0520.00% (+0.01)
Oct 03, 2024
2025 (Q1)
-0.15 / -0.11
-0.128.33% (<+0.01)
Jul 16, 2024
2024 (Q4)
-0.17 / -0.06
0.02-400.00% (-0.08)
Apr 04, 2024
2024 (Q3)
-0.15 / -0.16
-0.03-433.33% (-0.13)
Jan 05, 2024
2024 (Q2)
-0.07 / -0.05
0.01-600.00% (-0.06)
Oct 04, 2023
2024 (Q1)
-0.13 / -0.12
-0.06-100.00% (-0.06)
Jul 12, 2023
2023 (Q4)
0.02 / 0.02
0.01100.00% (+0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ANGO Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 15, 2025
$9.63$8.65-10.18%
Apr 02, 2025
$9.66$10.86+12.42%
Jan 08, 2025
$9.40$12.94+37.66%
Oct 03, 2024
$7.65$6.37-16.73%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Angiodynamics, Inc. (ANGO) report earnings?
Angiodynamics, Inc. (ANGO) is schdueled to report earning on Oct 02, 2025, Before Open (Confirmed).
    What is Angiodynamics, Inc. (ANGO) earnings time?
    Angiodynamics, Inc. (ANGO) earnings time is at Oct 02, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ANGO EPS forecast?
          ANGO EPS forecast for the fiscal quarter 2026 (Q1) is -0.12.

            AngioDynamics (ANGO) Earnings News

            Wider Q1 Loss Weighs on AngioDynamics (NASDAQ:ANGO) Stock
            Premium
            Market News
            Wider Q1 Loss Weighs on AngioDynamics (NASDAQ:ANGO) Stock
            3y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis